Moderna CEO says its mRNA vaccine could potentially offer protection for a ‘couple of years'
The duration of protection that Covid-19 shots offer remains an important and lingering question for scientists and regulators.


Moderna's COVID-19 vaccine technnology could revolutionise future treatments for infectious diseases and pandemics. Image: AP[/caption]The interim results of safety and primary efficacy of the vaccine's Phase 3 human trials were recently published in The New England Journal of Medicine. Evidence from clinical trials shows the vaccine was 94 percent effective at preventing lab-confirmed Covid-19 in people who were given two doses and no history of the infection. In mid-December 2020, the FDA approved the emergency use of the Moderna vaccine in people 18 years of age and older. Some 18 million doses have been supplied to the US government already – a fraction of the 800 million doses the country has secured for its citizens from multiple vaccine makers.The Moderna vaccine has also been authorized by Canadian health authorities to immunize citizens 18 years of age and older.

Careless Whispers: Scientists discover that plants can 'talk' to each other using smells
Life on Mars? European Space Agency’s Orbiter discovers ice water deposits at equator
Microsoft briefly overtakes Apple as the most valuable company, Apple back on top again
Even NASA is facing a tough time, starts layoffs following major budget cuts
ISRO, NASA's NISAR satellite to get ready by Jan-end, will monitor Earth's snow-covered regions
